Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population"
- PMID: 30986013
Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population"
Abstract
The authors of the manuscript "Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population" respond to a letter to the editor.
Comment on
-
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.Am J Manag Care. 2018 Apr;24(8 Suppl):S146-S155. Am J Manag Care. 2018. PMID: 29693361
-
Comment on generalizability of GLP-1 RA CVOTs in US T2D population.Am J Manag Care. 2019 Apr;25(4):170-171. Am J Manag Care. 2019. PMID: 30986012
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical